Trial Profile

Modifying Orphan Disease Evaluation (MODE) Study: A Multicenter, Open-Label Study of the Effects of CER-001 on Plaque Volume in Subjects with Homozygous Familial Hypercholesterolemia (HoFH).

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 06 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CER 001 (Primary)
Indications Hyperlipoproteinaemia type IIa
Focus Pharmacodynamics
Acronyms MODE
Sponsors ABIONYX Pharma; Cerenis Therapeutics

Most Recent Events

01 May 2015 Results published in the American Heart Journal.
04 Feb 2015 Status changed from active, no longer recruiting to completed as reported by the ClinicalTrials.gov record.
02 Jun 2014 According to a Cerenis media release, results were presented at the 82nd Congress of the European Atherosclerosis Society.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com